利福喷丁与利福平在肺结核治疗中的疗效及安全性比较  

Comparison of Efficacy and Safety of Rifapentine and Rifampicin in the Treatment of Pulmonary Tuberculosis

作　　者：于丹 刘宁[1] YU Dan;LIU Ning(Department of Respiratory Diseases,Shenyang Tenth People's Hospital,Shenyang 110044,China)

机构地区：[1]沈阳市第十人民医院呼吸一科,辽宁沈阳110044

出　　处：《中国医药指南》2020年第10期162-163,共2页Guide of China Medicine

摘　　要：目的研究利福喷丁与利福平在肺结核治疗中的治疗疗效以及安全性。方法研究对象选自本院2016年1月至2018年1月收治的160例肺结核患者,将所选患者按照治疗措施的不同,分为对照组80例,使用利福平进行治疗,另外80例患者作为观察组使用利福喷丁治疗,观察两组患者临床治疗疗效以及安全性。结果本次研究发现,通过对两组肺结核患者实施不同的治疗措施,两组患者病情均表现出不同程度的好转,但相较于对照组患者治疗有效率77.5%而言,观察组患者治疗有效率为96.25%,由此观察组治疗措施更优;且观察组患者治疗过程中出现6例(7.5%)肝功能异常的情况,对照组患者治疗过程中出现17例(21.25%)肝功能异常的情况,证明观察组患者治疗安全性更高,差异具有统计学意义(P<0.05)。结论对于肺结核患者使用利福喷丁进行治疗,在保证治疗质量的前提下,降低不良反应发生率,安全性高,应该在临床上加强其的推广。Objective To study the therapeutic efficacy and safety of rifapentine and rifampicin in the treatment of pulmonary tuberculosis.Methods The study subjects were selected from 160 patients with pulmonary tuberculosis admitted to our hospital from January to February 2018.The selected patients were divided into the control group according to different treatment measures,80 cases were treated with rifampicin,and 80 patients were treated.The patients were treated with rifapentine as an observation group,and the clinical efficacy and safety of the two groups were observed.Results This study found that the two groups of patients showed different degrees of improvement through different treatments for the two groups of pulmonary tuberculosis patients,but compared with the control group patients with effective rate of 77.5%,the observation group patients treated The effective rate was 96.25%,which resulted in better treatment in the observation group;and 6 patients(7.5%)had abnormal liver function during the treatment group,and 17 patients(21.25%)had liver function during the treatment.Abnormal conditions proved that the patients in the observation group had higher treatment safety,and the difference was statistically significant(P<0.05).Conclusion The treatment of rifapentine in patients with pulmonary tuberculosis should reduce the incidence of adverse reactions and ensure high safety under the premise of ensuring the quality of treatment.It should be strengthened in clinical practice.

关 键 词：利福喷丁 利福平 肺结核 安全性 

分 类 号：R521[医药卫生—内科学]